$1.69
2.42% today
Nasdaq, Sep 23, 09:49 pm CET
ISIN
US75955J2042
Symbol
RLMD

Relmada Therapeutics Inc Stock price

$1.65
+1.02 163.16% 1M
+1.35 446.36% 6M
+1.13 217.31% YTD
-1.85 52.86% 1Y
-28.89 94.60% 3Y
-35.88 95.60% 5Y
-19.31 92.13% 10Y
-58.35 97.25% 20Y
Nasdaq, Closing price Mon, Sep 22 2025
+0.12 7.84%
ISIN
US75955J2042
Symbol
RLMD
Industry

Key metrics

Basic
Market capitalization
$54.8m
Enterprise Value
$34.2m
Net debt
positive
Cash
$20.6m
Shares outstanding
33.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
3.4
Financial Health
Equity Ratio
77.5%
Return on Equity
-225.2%
ROCE
-441.0%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | $-105.6m
EBIT
$-70.5m | $-61.8m
Net Income
$-68.1m | $-65.3m
Free Cash Flow
$-50.2m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
22.9% | 26.3%
Net Income
21.7% | 18.3%
Free Cash Flow
-4.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-2.1
FCF per Share
$-1.5
Short interest
1.7%
Employees
17
Rev per Employee
$0.0
Show more

Is Relmada Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

Relmada Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Relmada Therapeutics Inc forecast:

4x Hold
57%
3x Sell
43%

Analyst Opinions

7 Analysts have issued a Relmada Therapeutics Inc forecast:

Hold
57%
Sell
43%

Financial data from Relmada Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 34 34
20% 20%
-
- Research and Development Expense 37 37
25% 25%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -71 -71
23% 23%
-
Net Profit -68 -68
22% 22%
-

In millions USD.

Don't miss a Thing! We will send you all news about Relmada Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Relmada Therapeutics Inc Stock News

Neutral
GlobeNewsWire
7 days ago
CORAL GABLES, Fla., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology-related and central nervous system indications, today announced that on September 15, 2025 it received written notice from the Nasdaq Stock Market LLC (Nasdaq) confirming that the Company ...
Neutral
GlobeNewsWire
13 days ago
CORAL GABLES, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology-related and central nervous system indications, today issued a Letter to Shareholders from Sergio Traversa, Chief Executive Officer.
Neutral
Seeking Alpha
about 2 months ago
Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Maged S. Shenouda - Chief Financial Officer Raj S.
More Relmada Therapeutics Inc News

Company Profile

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. It engages in the development of d-methadone receptor antagonist, which is a chemical entity that addresses areas of high unmet medical need in the treatment of central nervous system diseases and other disorders. The company was founded on May 31, 2012 and is headquartered in New York, NY.

Head office United States
CEO Sergio Traversa
Employees 17
Founded 2012
Website www.relmada.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today